Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment and is standard of care in treatment monitoring and decision...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Gökbuget, Nicola, Kantarjian, Hagop M., Brüggemann, Monika, Stein, Anthony S., Bargou, Ralf C., Dombret, Hervé, Fielding, Adele K., Heffner, Leonard, Rigal-Huguet, Françoise, Litzow, Mark, O’Brien, Susan, Zugmaier, Gerhard, Gao, Shan, Nagorsen, Dirk, Forman, Stephen J., Topp, Max S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849936/
https://ncbi.nlm.nih.gov/pubmed/31648325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000457
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars